Medexus Pharmaceuticals Stock Analysis

Medexus Stock Analysis Notes

The company has price-to-book ratio of 1.3. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Medexus Pharmaceuticals last dividend was issued on the 19th of December 2018. The entity had 1:15 split on the 19th of December 2018. To find out more about Medexus Pharmaceuticals contact Kenneth dEntremont at 877 422 5242 or learn more at https://www.medexus.com.

Medexus Pharmaceuticals Investment Alerts

Medexus Largest EPS Surprises

View All Earnings Estimates

Medexus Market Capitalization

The company currently falls under 'Micro-Cap' category with a current market capitalization of 91.1 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Medexus Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Medexus Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Medexus Profitablity

Management Efficiency

Medexus Pharmaceuticals has return on total asset (ROA) of 0.0254 % which means that it generated a profit of $0.0254 on every $100 spent on assets. This is way below average. Medexus Pharmaceuticals' management efficiency ratios could be used to measure how well Medexus Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 13th of February 2026, Return On Tangible Assets is likely to grow to 0.02. Also, Return On Capital Employed is likely to grow to 0.10. At this time, Medexus Pharmaceuticals' Return On Tangible Assets are very stable compared to the past year. As of the 13th of February 2026, Debt To Assets is likely to grow to 0.42, while Intangible Assets are likely to drop about 43.7 M.

Technical Drivers

As of the 13th of February 2026, Medexus Pharmaceuticals secures the Downside Deviation of 2.09, risk adjusted performance of 0.0254, and Mean Deviation of 1.64. In connection with fundamental indicators, the technical analysis model lets you check existing technical drivers of Medexus Pharmaceuticals, as well as the relationship between them.

Medexus Pharmaceuticals Price Movement Analysis

Medexus Pharmaceuticals Outstanding Bonds

Medexus Pharmaceuticals Predictive Daily Indicators

Medexus Pharmaceuticals Forecast Models

Medexus Pharmaceuticals' time-series forecasting models are one of many Medexus Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Medexus Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Medexus Pharmaceuticals Debt to Cash Allocation

Medexus Pharmaceuticals has accumulated 37.18 M in total debt. Debt can assist Medexus Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Medexus Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Medexus Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Medexus to invest in growth at high rates of return. When we think about Medexus Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Medexus Pharmaceuticals Total Assets Over Time

Medexus Pharmaceuticals Assets Financed by Debt

The debt-to-assets ratio shows the degree to which Medexus Pharmaceuticals uses debt to finance its assets. It includes both long-term and short-term borrowings maturing within one year. It also includes both tangible and intangible assets, such as goodwill.

Medexus Pharmaceuticals Debt Ratio

42.0

It appears that about 58% of Medexus Pharmaceuticals' assets are financed through equity. Typically, companies with high debt-to-asset ratios are said to be highly leveraged. The higher the ratio, the greater risk will be associated with the Medexus Pharmaceuticals' operation. In addition, a high debt-to-assets ratio may indicate a low borrowing capacity of Medexus Pharmaceuticals, which in turn will lower the firm's financial flexibility.

Medexus Pharmaceuticals Corporate Bonds Issued

Medexus Net Debt

Stock analysis is the technique used by a trader or investor to examine and evaluate how Medexus Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Medexus shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Medexus Pharmaceuticals. By using and applying Medexus Stock analysis, traders can create a robust methodology for identifying Medexus entry and exit points for their positions.

Medexus Pharmaceuticals financial ratios help investors to determine whether Medexus Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Medexus with respect to the benefits of owning Medexus Pharmaceuticals security.